Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Brain Neoplasms 151Glioblastoma 147Glioma 95Neuroblastoma 50Medulloblastoma 33Central Nervous System Neoplasms 27Astrocytoma 27Neoplasms 24Ependymoma 23Sarcoma 22Carcinoma, Non-Small-Cell Lung 22Neurofibromatosis 1 21Melanoma 20Breast Neoplasms 20Rhabdomyosarcoma 18Osteosarcoma 18Sarcoma, Ewing 16Lung Neoplasms 16Gliosarcoma 16Rhabdoid Tumor 15Oligodendroglioma 15Diffuse Intrinsic Pontine Glioma 14Wilms Tumor 13Meningioma 13Hepatoblastoma 13Recurrence 12Neurofibroma, Plexiform 11Neoplasm Metastasis 11Meningeal Carcinomatosis 11Lymphoma, Non-Hodgkin 11

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Metastatic Breast Cancer × CNS × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡